

## **SUMMARY OF COHERE FINLAND'S RECOMMENDATION FOR THE USE OF TRASTUZUMAB DERUXTECAN IN THE TREATMENT OF METASTATIC BREAST CANCER**

**At its meeting of 16 June 2026, the Council for Choices in Health Care in Finland (COHERE Finland) adopted three recommendations for the use of trastuzumab deruxtecan in the treatment of metastatic breast cancer.**

COHERE Finland's recommendation for trastuzumab deruxtecan consists of the following three sub-indications for the treatment of metastatic breast cancer:

Trastuzumab deruxtecan is included in the national range of services for the treatment of HER2-positive breast cancer in patients who have previously received at least one anti-HER2-based therapy.

COHERE Finland requires that the marketing authorisation holder and the buyer agree on a price significantly lower than the public wholesale price.

In COHERE Finland's view, the effects of trastuzumab deruxtecan treatment in the second-line treatment of HER2-positive breast cancer are favourable compared with the comparator treatment, trastuzumab emtansine, but the costs are high. The treatment's effectiveness has also not been questioned in the reviewed recommendations from other countries, although these recommendations emphasise the reasonableness of costs in relation to the current treatment in use.

Trastuzumab deruxtecan is included in the national range of services for the treatment of unresectable or metastatic HER2-low breast cancer in adult patients who have previously received chemotherapy for metastatic disease, or whose disease has recurred during adjuvant chemotherapy or within six months of its completion.

COHERE Finland requires that the marketing authorisation holder and the buyer agree on a price significantly lower than the public wholesale price.

In COHERE Finland's view, the effects of trastuzumab deruxtecan treatment in unresectable or metastatic HER2-low breast cancer are fairly favourable compared with the comparator treatments, but the costs are high. The adoption of this treatment is recommended in the recommendations of other countries, with the exception of the British National Institute for Health and Care Excellence (NICE), but these recommendations emphasise the reasonableness of costs in relation to the current treatment in use.

Trastuzumab deruxtecan is not included in the national range of services for the treatment of unresectable or metastatic hormone receptor-positive HER2-low or HER2-ultralow breast cancer in patients who have received at least one endocrine therapy for metastatic disease, and for whom endocrine therapy is not considered suitable as the next line of treatment.

In COHERE Finland's view, no sufficient evidence is yet available on the effects of trastuzumab deruxtecan treatment in unresectable or metastatic hormone receptor-positive HER2-low or HER2-ultralow breast cancer, and the costs are high compared with the comparator treatments. Cost-effectiveness has not been assessed from a Finnish perspective.

This is a summary of a recommendation adopted by the Council for Choices in Health Care in Finland (COHERE Finland). The actual recommendation and the related background material are available in Finnish on the website of COHERE Finland under [Valmiit suositukset](#).

The summary of the recommendation is also available in [Swedish](#) and [English](#) on the website.

The Council for Choices in Health Care in Finland (COHERE Finland) works in conjunction with the Ministry of Social Affairs and Health, and its task is to issue recommendations on services that should be included in the range of public health services. Further information about service choices in healthcare is available [on the COHERE Finland website](#).